Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50


Breakdown of Immune Tolerance in AIRE-Deficient Rats Induces a Severe Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-like Autoimmune Disease.

Ossart J, Moreau A, Autrusseau E, Ménoret S, Martin JC, Besnard M, Ouisse LH, Tesson L, Flippe L, Kisand K, Peterson P, Hubert FX, Anegon I, Josien R, Guillonneau C.

J Immunol. 2018 Aug 1;201(3):874-887. doi: 10.4049/jimmunol.1701318. Epub 2018 Jun 29.


Advances on CD8+ Treg Cells and Their Potential in Transplantation.

Bézie S, Anegon I, Guillonneau C.

Transplantation. 2018 Sep;102(9):1467-1478. doi: 10.1097/TP.0000000000002258. Review.


Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/- Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice.

Bézie S, Meistermann D, Boucault L, Kilens S, Zoppi J, Autrusseau E, Donnart A, Nerrière-Daguin V, Bellier-Waast F, Charpentier E, Duteille F, David L, Anegon I, Guillonneau C.

Front Immunol. 2018 Jan 31;8:2014. doi: 10.3389/fimmu.2017.02014. eCollection 2017.


In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients.

Bézie S, Usal C, Guillonneau C.

J Vis Exp. 2017 Aug 12;(126). doi: 10.3791/55510.


Immunoregulatory properties of the cytokine IL-34.

Guillonneau C, Bézie S, Anegon I.

Cell Mol Life Sci. 2017 Jul;74(14):2569-2586. doi: 10.1007/s00018-017-2482-4. Epub 2017 Mar 3. Review.


Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.

Picarda E, Bézie S, Boucault L, Autrusseau E, Kilens S, Meistermann D, Martinet B, Daguin V, Donnart A, Charpentier E, David L, Anegon I, Guillonneau C.

JCI Insight. 2017 Feb 9;2(3):e90088. doi: 10.1172/jci.insight.90088.


Improved Analyses of CD8+ T Cell Specificities Using Multimers of Peptide MHC Complexes Coupled to DNA Barcodes.

Guillonneau C, David L, Anegon I.

Transplantation. 2017 Feb;101(2):219-221. doi: 10.1097/TP.0000000000001601. No abstract available.


Compensatory Regulatory Networks between CD8 T, B, and Myeloid Cells in Organ Transplantation Tolerance.

Bézie S, Picarda E, Ossart J, Martinet B, Anegon I, Guillonneau C.

J Immunol. 2015 Dec 15;195(12):5805-15. doi: 10.4049/jimmunol.1500473. Epub 2015 Nov 9.


IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Bézie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K, Anegon I, Guillonneau C.

J Clin Invest. 2015 Oct 1;125(10):3952-64. doi: 10.1172/JCI81227. Epub 2015 Sep 21.


Efficacy of Myeloid Derived Suppressor Cells on Transplant Survival.

Guillonneau C.

Transplantation. 2015 Oct;99(10):2017-9. doi: 10.1097/TP.0000000000000858. No abstract available.


Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells.

Bézie S, Picarda E, Tesson L, Renaudin K, Durand J, Ménoret S, Mérieau E, Chiffoleau E, Guillonneau C, Caron L, Anegon I.

PLoS One. 2015 Mar 12;10(3):e0119686. doi: 10.1371/journal.pone.0119686. eCollection 2015.


[Key role of allopeptide-specific CD8(+) Tregs in transplantation].

Picarda É, Ossart J, Bézie S, Guillonneau C.

Med Sci (Paris). 2015 Jan;31(1):22-4. doi: 10.1051/medsci/20153101007. Epub 2015 Feb 6. French. No abstract available.


MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection.

Picarda E, Bézie S, Venturi V, Echasserieau K, Mérieau E, Delhumeau A, Renaudin K, Brouard S, Bernardeau K, Anegon I, Guillonneau C.

J Clin Invest. 2014 Jun;124(6):2497-512. doi: 10.1172/JCI71533. Epub 2014 May 1.


Preemptive priming readily overcomes structure-based mechanisms of virus escape.

Valkenburg SA, Gras S, Guillonneau C, Hatton LA, Bird NA, Twist KA, Halim H, Jackson DC, Purcell AW, Turner SJ, Doherty PC, Rossjohn J, Kedzierska K.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5570-5. doi: 10.1073/pnas.1302935110. Epub 2013 Mar 14.


Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope.

Chen AT, Cornberg M, Gras S, Guillonneau C, Rossjohn J, Trees A, Emonet S, de la Torre JC, Welsh RM, Selin LK.

PLoS Pathog. 2012;8(4):e1002633. doi: 10.1371/journal.ppat.1002633. Epub 2012 Apr 19.


Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A viruses.

Denton AE, Wesselingh R, Gras S, Guillonneau C, Olson MR, Mintern JD, Zeng W, Jackson DC, Rossjohn J, Hodgkin PD, Doherty PC, Turner SJ.

J Immunol. 2011 Dec 1;187(11):5733-44. doi: 10.4049/jimmunol.1003937. Epub 2011 Oct 28.


Structural basis for enabling T-cell receptor diversity within biased virus-specific CD8+ T-cell responses.

Day EB, Guillonneau C, Gras S, La Gruta NL, Vignali DA, Doherty PC, Purcell AW, Rossjohn J, Turner SJ.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9536-41. doi: 10.1073/pnas.1106851108. Epub 2011 May 23.


T-cell receptor specificity of CD8(+) Tregs in allotransplantation.

Picarda E, Anegon I, Guillonneau C.

Immunotherapy. 2011 Apr;3(4 Suppl):35-7. doi: 10.2217/imt.11.37. Review.


Phenotypic and functional characterization of CD8(+) T regulatory cells.

Ménoret S, Guillonneau C, Bezié S, Caron L, Anegon I, Li XL.

Methods Mol Biol. 2011;677:63-83. doi: 10.1007/978-1-60761-869-0_5.


CD8+ regulatory T cells in solid organ transplantation.

Guillonneau C, Picarda E, Anegon I.

Curr Opin Organ Transplant. 2010 Dec;15(6):751-6. doi: 10.1097/MOT.0b013e32834016d1. Review.


Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.

Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW, Rossjohn J, Doherty PC, Turner SJ, Kedzierska K.

PLoS Pathog. 2010 Aug 12;6(8):e1001039. doi: 10.1371/journal.ppat.1001039.


Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance.

Li XL, Ménoret S, Bezie S, Caron L, Chabannes D, Hill M, Halary F, Angin M, Heslan M, Usal C, Liang L, Guillonneau C, Le Mauff B, Cuturi MC, Josien R, Anegon I.

J Immunol. 2010 Jul 15;185(2):823-33. doi: 10.4049/jimmunol.1000120. Epub 2010 Jun 11.


Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition.

Theodossis A, Guillonneau C, Welland A, Ely LK, Clements CS, Williamson NA, Webb AI, Wilce JA, Mulder RJ, Dunstone MA, Doherty PC, McCluskey J, Purcell AW, Turner SJ, Rossjohn J.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5534-9. doi: 10.1073/pnas.1000032107. Epub 2010 Mar 8.


Diversity and clonotypic composition of influenza-specific CD8+ TCR repertoires remain unaltered in the absence of Aire.

Kedzierska K, Valkenburg SA, Guillonneau C, Hubert FX, Cukalac T, Curtis JM, Stambas J, Scott HS, Kedzierski L, Venturi V, Davenport MP.

Eur J Immunol. 2010 Mar;40(3):849-58. doi: 10.1002/eji.200939918.


Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3330-5. doi: 10.1073/pnas.0813309106. Epub 2009 Feb 11.


Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy.

Kedzierska K, Guillonneau C, Gras S, Hatton LA, Webby R, Purcell AW, Rossjohn J, Doherty PC, Turner SJ.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19408-13. doi: 10.1073/pnas.0810274105. Epub 2008 Dec 1.


Frontiers in immunology research network--2008 International Conference.

Mintern JD, Guillonneau C.

IDrugs. 2008 Oct;11(10):710-2. No abstract available.


Killer T cells in influenza.

Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, La Gruta NL.

Pharmacol Ther. 2008 Nov;120(2):186-96. doi: 10.1016/j.pharmthera.2008.08.007. Epub 2008 Aug 28. Review.


Preparation and affinity profile of novel nicotinic ligands.

Charton Y, Guillonneau C, Lockhart B, Lestage P, Goldstein S.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2188-93. doi: 10.1016/j.bmcl.2007.12.075. Epub 2008 Jan 26.


Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients.

Guillonneau C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, Usal C, Veziers J, Anegon I, Vanhove B.

J Immunol. 2007 Dec 15;179(12):8164-71.


Cutting edge: Tissue-resident memory CTL down-regulate cytolytic molecule expression following virus clearance.

Mintern JD, Guillonneau C, Carbone FR, Doherty PC, Turner SJ.

J Immunol. 2007 Dec 1;179(11):7220-4.


CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase.

Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Hervé C, Li XL, Heslan M, Usal C, Tesson L, Ménoret S, Saoudi A, Le Mauff B, Josien R, Cuturi MC, Anegon I.

J Clin Invest. 2007 Apr;117(4):1096-106.


Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.

Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, Josien R, Anegon I, Lowenstein PR, Castro MG.

J Immunol. 2006 Mar 15;176(6):3566-77.


Accumulation of T cells with potent regulatory properties and restricted Vbeta7-TCR rearrangements in tolerated allografts.

Heslan JM, Beriou G, Le Luduec JB, Guillonneau C, Anegon I, Soulillou JP, Cuturi MC, Chiffoleau E.

Transplantation. 2005 Nov 27;80(10):1476-84.


Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.

Guillonneau C, Aubry V, Renaudin K, Séveno C, Usal C, Tezuka K, Anegon I.

Transplantation. 2005 Aug 27;80(4):546-54.


Identification of a new member of the CD20/FcepsilonRIbeta family overexpressed in tolerated allografts.

Louvet C, Chiffoleau E, Heslan M, Tesson L, Heslan JM, Brion R, Bériou G, Guillonneau C, Khalife J, Anegon I, Cuturi MC.

Am J Transplant. 2005 Sep;5(9):2143-53.


Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.

Guillonneau C, Aubry V, Renaudin K, Séveno C, Usal C, Tezuka K, Anegon I.

Transplantation. 2005 Jul 27;80(2):255-63. Erratum in: Transplantation. 2005 Aug 27;80(4):545. Corrected and republished in: Transplantation. 2005 Aug 27;80(4):546-54.


Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression.

Bériou G, Pêche H, Guillonneau C, Merieau E, Cuturi MC.

Transplantation. 2005 Apr 27;79(8):969-72.


Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues.

Guillonneau C, Nault A, Raimbaud E, Léonce S, Kraus-Berthier L, Pierré A, Goldstein S.

Bioorg Med Chem. 2005 Jan 3;13(1):175-84.


Long term transgene expression by hepatocytes transduced with retroviral vectors requires induction of immune tolerance to the transgene.

Puppi J, Guillonneau C, Pichard V, Bellodi-Privato M, Cuturi MC, Anegon I, Ferry N.

J Hepatol. 2004 Aug;41(2):222-8.


Application of gene transfer technologies to transplantation.

Anegon I, Guillonneau C, Hill M, Chauveau C.

Ther Drug Monit. 2004 Jun;26(3):248-50. Review. No abstract available.


The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection.

Guillonneau C, Louvet C, Renaudin K, Heslan JM, Heslan M, Tesson L, Vignes C, Guillot C, Choi Y, Turka LA, Cuturi MC, Anegon I, Josien R.

J Immunol. 2004 Feb 1;172(3):1619-29.


Synthesis and pharmacological evaluation of new 1,2-dithiolane based antioxidants.

Guillonneau C, Charton Y, Ginot YM, Fouquier-d'Hérouël MV, Bertrand M, Lockhart B, Lestage P, Goldstein S.

Eur J Med Chem. 2003 Jan;38(1):1-11.


Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig.

Guillot C, Ménoret S, Guillonneau C, Braudeau C, Castro MG, Lowenstein P, Anegon I.

Blood. 2003 Apr 15;101(8):3325-33. Epub 2002 Dec 19.


Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.

Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.

Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. Epub 2002 Jun 25.


Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection.

Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Ménoret S, Braudeau C, Tesson L, Renaudin K, Castro MG, Löwenstein PR, Anegon I.

J Immunol. 2002 Feb 15;168(4):1600-9.


Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity.

Guillonneau C, PierréA, Charton Y, Guilbaud N, Kraus-Berthier L, Léonce S, Michel A, Bisagni E, Atassi G.

J Med Chem. 1999 Jun 17;42(12):2191-203.


Synthesis and biological evaluation of 6-(9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazol-1-yl)picolinic amides as new olivacine derivatives.

Landras C, Jasztold-Howorko R, Pierré A, Léonce S, Guilbaud N, Kraus-Berthier L, Guillonneau C, Rolland Y, Atassi G, Bisagni E.

Chem Pharm Bull (Tokyo). 1996 Nov;44(11):2169-72.


S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.

Breugnot C, Privat S, Guillonneau C, Regnier G, Bouzom F, Vilaine JP, Lenaers A.

J Pharmacol Exp Ther. 1994 May;269(2):515-20.


Protective effect of S12340 on cardiac cells exposed to oxidative stress.

Iliou JP, Thollon C, Robin F, Cambarrat C, Guillonneau C, Régnier G, Lenaers A, Vilaine JP.

Eur J Pharmacol. 1993 Oct 1;248(3):263-72.


Supplemental Content

Loading ...
Support Center